Search results
Results from the WOW.Com Content Network
Hypromellose , short for hydroxypropyl methylcellulose (HPMC), is a semisynthetic, inert, viscoelastic polymer used in eye drops, as well as an excipient and controlled-delivery component in oral medicaments, found in a variety of commercial products.
A glucose sensitive treatment method for diabetes have long been pursued by science since 1979. [4] Such protein is expected to solve the problem of fluctuations of blood sugar levels. For diabetes patients, skipping meal alone could lead to hypoglycemia, which is a common complication could cause loss of consciousness or seizures. [5]
Diabetes is very common. The Centers for Disease Control and Prevention (CDC) notes that 38.4 million people in the United States are currently living with diabetes. That’s 11.6 percent of the ...
Type 2 diabetes is the most common type of diabetes. Treatments include agents that (1) increase the amount of insulin secreted by the pancreas, (2) increase the sensitivity of target organs to insulin, (3) decrease the rate at which glucose is absorbed from the gastrointestinal tract, and (4) increase the loss of glucose through urination.
Insulin lispro (brand name Humalog) was granted marketing authorization in the European Union in April 1996, [3] and it was approved for use in the United States in June 1996. [9] [15] Insulin lispro (brand name Liprolog) was granted marketing authorization in the European Union in May 1997, [4] and again in August 2001. [16]
The first cost-effectiveness analysis of this nature was conducted from a societal perspective in the Swedish setting in 2013, finding that insulin degludec would be cost-effective relative to insulin glargine in the treatment of type 1 diabetes, and type 2 diabetes as part of either a basal or basal-insulin regimen. [28]
In patients with diabetes mellitus type 1, alpha-glucosidase inhibitors use has not been officially approved by the Food and Drug Administration in the US but some data exists on the effectiveness in this population, showing potential benefits weighted against an increased risk of hypoglycemia. [18]
Pramlintide has been approved on 3/16/2005 by the FDA, for use by type 1 and type 2 diabetic patients who use insulin. [6] (subscription required) Pramlintide allows patients to use less insulin, lowers average blood sugar levels, and substantially reduces what otherwise would be a large unhealthy rise in blood sugar that occurs in diabetics right after eating.